Trial Profile
Exploratory Study on the Kinetics of Psoriasis Symptoms, Pruritus Intensity and Lesional Biomarkers in Patients With Moderate to Severe Plaque-type Psoriasis Treated With Subcutaneous Secukinumab (300 mg) During a 16 Week Open-label run-in Phase Followed by a 16 Week Randomized, Double-blind, Placebo-controlled Withdrawal Phase
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2019
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PSORITUS
- Sponsors Novartis Pharmaceuticals
- 21 Sep 2016 Status changed from recruiting to completed.
- 06 Feb 2015 New trial record